Richard Mason, Apollo Therapeutics CEO

UK biotech brings in $226M Se­ries C

Apol­lo Ther­a­peu­tics is reel­ing in a $226.5 mil­lion Se­ries C round, the biotech said Wednes­day.

The fi­nanc­ing is two-pronged: It aims to ad­vance Apol­lo’s clin­i­cal pro­grams and back its drug dis­cov­ery ef­forts, and po­ten­tial­ly li­cense or ac­quire clin­i­cal-stage can­di­dates that meet cer­tain cri­te­ria.

“This lat­est fundrais­ing en­ables us to take our most ad­vanced pro­grams to key clin­i­cal val­ue in­flec­tion points,” Apol­lo CEO Richard Ma­son said in a press re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.